Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-03-26
2001-02-06
Elliott, George C. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500, C435S006120, C435S091100, C435S325000, C435S375000
Reexamination Certificate
active
06184212
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compositions and methods for modulating expression of the human mdm2 gene, a naturally present cellular gene implicated in abnormal cell proliferation and tumor formation. This invention is also directed to methods for inhibiting hyperproliferation of cells; these methods can be used diagnostically or therapeutically. Furthermore, this invention is directed to treatment of conditions associated with expression of the human mdm2 gene.
BACKGROUND OF THE INVENTION
Inactivation of tumor suppressor genes leads to unregulated cell proliferation and is a cause of tumorigenesis. In many tumors, the tumor suppressors, p53 or Rb (retinoblastoma) are inactivated. This can occur either by mutations within these genes, or by overexpression of the mdm2 gene. The mdm2 protein physically associates with both p53 and Rb, inhibiting their function. The levels of mdm2 are maintained through a feedback loop mechanism with p53. Overexpression of mdm2 effectively inactivates p53 and promotes cell proliferation.
The role of p53 in apoptosis and tumorigenesis is well-known in the art (see, in general, Canman, C. E. and Kastan, M. B.,
Adv. Pharmacol
., 1997, 41, 429-460). Mdm2 has been shown to regulate p53's apoptotic functions (Chen, J., et al.,
Mol. Cell Biol
., 1996, 16, 2445-2452; Haupt, Y., et al.,
EMBO J
., 1996, 15, 1596-1606). Overexpression of mdm2 protects tumor cells from p53-mediated apoptosis. Thus, mdm2 is an attractive target for cancers associated with altered p53 expression.
Amplification of the mdm2 gene is found in many human cancers, including soft tissue sarcomas, astrocytomas, glioblastomas, breast cancers and non-small cell lung carcinomas. In many blood cancers, overexpression of mdm2 can occur with a normal copy number. This has been attributed to enhanced translation of mdm2 mRNA, which is thought to be related to a distinct 5′-untranslated region (5′-UTR) which causes the transcript to be translated more efficiently than the normal mdm2 transcript. Landers et al.,
Cancer Res
. 57, 3562, (1997).
Several approaches have been used to disrupt the interaction between p53 and mdm2. Small peptide inhibitors, screened from a phage display library, have been shown in ELISA assays to disrupt this interaction [Bottger et al.,
J. Mol. Biol
., 269, 744 (1997)]. Microinjection of an anti-mdm2 antibody targeted to the p53-binding domain of mdm2 increased p53-dependent transcription [Blaydes et al.,
Oncogene
, 14, 1859 (1997)].
A vector-based antisense approach has been used to study the function of mdm2. Using a rhabdomyosarcoma model, Fiddler et al. [
Mol. Cell Biol
., 16, 5048 (1996)] demonstrated that amplified mdm2 inhibits the ability of MyoD to function as a transcription factor. Furthermore, expression of full-length antisense mdm2 from a cytomegalovirus promoter-containing vector restores muscle-specific gene expression.
Antisense oligonucleotides have also been useful in understanding the role of mdm2 in regulation of p53. An antisense oligonucleotide directed to the mdm2 start codon allowed cisplatin-induced p53-mediated apoptosis to occur in a cell line overexpressing mdm2 [Kondo et al.,
Oncogene
, 10, 2001 (1995)]. The same oligonucleotide was found to inhibit the expression of P-glycoprotein [Kondo et al.,
Br. J. Cancer
, 74, 1263 (1996)]. P-glycoprotein was shown to be induced by mdm2. Teoh et al [
Blood
, 90, 1982 (1997)] demonstrated that treatment with an identical mdm2 antisense oligonucleotide or a shorter version within the same region in a tumor cell line decreased DNA synthesis and cell viability and triggered apoptosis.
Chen et al. [
Proc. Natl. Acad. Sci. USA
, 95, 195 (1998); WO 99/10486] disclose antisense oligonucleotides targeted to the coding region of mdm2. A reduction in mdm2 RNA and protein levels was seen, and transcriptional activity from a p53-responsive promoter was increased after oligonucleotide treatment of JAR (choriocarcinoma) or SJSA (osteosarcoma) cells.
WO 93/20238 and WO 97/09343 disclose, in general, the use of antisense constructs, antisense oligonucleotides, ribozymes and triplex-forming oligonucleotides to detect or to inhibit expression of mdm2. EP 635068B1, issued Nov. 5, 1997, describes methods of treating in vitro neoplastic cells with an inhibitor of mdm2, and inhibitory compounds, including antisense oligonucleotides and triple-strand forming oligonucleotides.
There remains a long-felt need for improved compositions and methods for inhibiting mdm2 gene expression.
SUMMAY OF THE INVENTION
The present invention provides antisense compounds which are targeted to nucleic acids encoding human mdm2 and are capable of modulating, and preferably, inhibiting mdm2 expression. The present invention also provides chimeric compounds targeted to nucleic acids encoding human mdm2. The antisense compounds of the invention are believed to be useful both diagnostically and therapeutically, and are believed to be particularly useful in the methods of the present invention.
The present invention also comprises methods of inhibiting the expression of human mdm2, particularly the increased expression resulting from amplification of mdm2. These methods are believed to be useful both therapeutically and diagnostically as a consequence of the association between mdm2 expression and hyperproliferation. These methods are also useful as tools, for example, for detecting and determining the role of mdm2 expression in various cell functions and physiological processes and conditions and for diagnosing conditions associated with mdm2 expression.
The present invention also comprises methods of inhibiting hyperproliferation of cells using compounds of the invention. These methods are believed to be useful, for example, in diagnosing mdm2-associated cell hyperproliferation. Methods of treating abnormal proliferative conditions associated with mdm2 are also provided. These methods employ the antisense compounds of the invention. These methods are believed to be useful both therapeutically and as clinical research and diagnostic tools.
DETAILED DESCRIPTION OF THE INVENTION
Tumors often result from genetic changes in cellular regulatory genes. Among the most important of these are the tumor suppressor genes, of which p53 is the most widely studied. Approximately half of all human tumors have a mutation in the p53 gene. This mutation disrupts the ability of the p53 protein to bind to DNA and act as a transcription factor. Hyperproliferation of cells occurs as a result. Another mechanism by which p53 can be inactivated is through overexpression of mdm2, which regulates p53 activity in a feedback loop. The mdm2 protein binds to p53 in its DNA binding region, preventing its activity. Mdm2 is amplified in some human tumors, and this amplification is diagnostic of neoplasia or the potential therefor. Over one third of human sarcomas have elevated mdm2 sequences. Elevated expression may also be involved in other tumors including but not limited to those in which p53 inactivation has been implicated. These include colorectal carcinoma, lung cancer and chronic myelogenous leukemia.
Many abnormal proliferative conditions, particularly hyperproliferative conditions, are believed to be associated with increased mdm2 expression and are, therefore believed to be responsive to inhibition of mdm2 expression. Examples of these hyperproliferative conditions are cancers, psoriasis, blood vessel stenosis (e.g., restenosis or atherosclerosis), and fibrosis, e.g., of the lung or kidney. Increased levels of wild-type or mutated p53 have been found in some cancers (Nagashima, G., et al.,
Acta Neurochir
. (
Wein
), 1999, 141, 53-61; Fiedler, A., et al.,
Langenbecks Arch. Surg
., 1998, 383, 269-275). Increased levels of p53 is also associated with resistance of a cancer to a chemotherapeutic drug (Brown, R., et al.,
Int. J. Cancer
, 1993, 55, 678-684). These diseases or conditions may be amenable to treatment by induction of mdm2 expression.
The prese
Cowsert Lex M.
Graham Mark J.
Miraglia Loren J.
Monia Brett P.
Nero Pamela
Elliott George C.
Epps Janet
Isis Pharmaceuticals , Inc.
Law Offices of Jane Massey Licata
LandOfFree
Antisense modulation of human mdm2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of human mdm2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of human mdm2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2609993